Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 270,200 shares, a growth of 79.2% from the January 31st total of 150,800 shares. Based on an average trading volume of 540,300 shares, the short-interest ratio is currently 0.5 days. Approximately 10.2% of the company’s shares are sold short.

Hedge Funds Weigh In On Traws Pharma

A number of large investors have recently modified their holdings of the company. Millennium Management LLC purchased a new position in Traws Pharma in the 4th quarter worth approximately $89,000. Renaissance Technologies LLC bought a new stake in shares of Traws Pharma in the fourth quarter worth $89,000. Geode Capital Management LLC acquired a new stake in Traws Pharma in the fourth quarter valued at $185,000. Boothbay Fund Management LLC bought a new position in Traws Pharma during the 4th quarter valued at $252,000. Finally, Vestal Point Capital LP bought a new stake in shares of Traws Pharma in the 4th quarter worth about $666,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Stock Down 30.8 %

Shares of NASDAQ TRAW traded down $1.02 on Monday, reaching $2.29. 1,478,929 shares of the company traded hands, compared to its average volume of 130,726. The firm’s 50 day moving average is $7.26. Traws Pharma has a fifty-two week low of $2.24 and a fifty-two week high of $27.50. The company has a market capitalization of $8.36 million, a PE ratio of -0.02 and a beta of 1.10.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.